The objectives of this study were to determine nelfinavir (NFV) and its metabolite M8 pharmacokinetic parameters and their variability in HIV/HCV co-infected patients and in HIV-positive controls with negative hepatitis serology, and to evaluate the opportunity of developing individualizes dosing strategies for HIV/HCV-positive subjects with liver dysfunction.
Clinical pharmacokinetics of nelfinavir and its metabolites M8 in HIV/HCV coinfected patients with cirrhosis / Regazzi, M. B.; Villani, P.; Zucchi, P.; Cusato, M.; Sighinolfi, L.; Catania, A.; Guaraldi, Giovanni; Calzetti, C.; Giacomazzi, D.; Stoppini, L.; Rossi, M. C.; Castelli, P.; Palvarini, L.; Maserati, R.. - STAMPA. - not applicable:(2003), pp. 14: P3.5-14: P3.5. (Intervento presentato al convegno 4th International workshop on Clinical Pharmacology of HIV Therapy tenutosi a Cannes, France nel 27-29 March 2003).
Clinical pharmacokinetics of nelfinavir and its metabolites M8 in HIV/HCV coinfected patients with cirrhosis
GUARALDI, Giovanni;
2003
Abstract
The objectives of this study were to determine nelfinavir (NFV) and its metabolite M8 pharmacokinetic parameters and their variability in HIV/HCV co-infected patients and in HIV-positive controls with negative hepatitis serology, and to evaluate the opportunity of developing individualizes dosing strategies for HIV/HCV-positive subjects with liver dysfunction.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
